Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed Phase 2 Interventional

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

NCT00000918
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 20, 2026, 1:01 AM EDT
Active, not recruiting Not applicable Interventional

Community-based Education, Navigation, and Support Intervention for Military Veterans

NCT05343169
View directory record Official record
Conditions
Overdose, Opioid Use Disorder, HIV Infections
Interventions
Overdose Education and Naloxone Distribution, Advanced Education in Safer Substance Use, Treatment, and Self-Care, Social Service and Health Navigation, Peer Social Support
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*

NCT00511368
View directory record Official record
Conditions
HIV Infections
Interventions
matching placebo, Bevirimat
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 20, 2026, 1:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Qualitative Assessment of Implementing Routine Rapid HIV Testing

NCT00680862
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Not applicable Interventional Results available

R5 Integrase Study in HIV-1 Naive Patients

NCT01204905
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Maraviroc in combination
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Not applicable Interventional Results available

An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

NCT05709860
View directory record Official record
Conditions
HIV Infections, Electronic Health Record, Primary Health Care
Interventions
EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Results available

Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy

NCT02342223
View directory record Official record
Conditions
HIV Facial Lipoatrophy
Interventions
Voluma
Device
Lead sponsor
Jared Jagdeo, MD, MS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 20, 2026, 1:01 AM EDT
Terminated Phase 1 Interventional

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

NCT02134886
View directory record Official record
Conditions
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 20, 2026, 1:01 AM EDT
Completed No phase listed Observational Results available

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Not applicable Interventional

Promoting Adherence to Anti-HIV Drug Regimens

NCT00051805
View directory record Official record
Conditions
HIV Infections
Interventions
Promotion of adherence to ARV medications
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 18, 2007 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Not applicable Interventional

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

NCT00002094
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

NCT00001095
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 1:01 AM EDT
Completed No phase listed Observational

Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine

NCT00000828
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals

NCT00000736
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
43
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 1:01 AM EDT
Completed No phase listed Observational

Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

NCT01536899
View directory record Official record
Conditions
HIV Positive, Marijuana Smoking
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

NCT00002262
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tumor Necrosis Factor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 1:01 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

NCT05217641
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 1:01 AM EDT
Completed No phase listed Observational

COVID-19 in Patients With HIV

NCT04333953
View directory record Official record
Conditions
HIV/AIDS, COVID-19, SARS-CoV-2
Interventions
No intervention
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

NCT00428519
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo, Aprepitant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 20, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

NCT03968211
View directory record Official record
Conditions
Immune Deficiency
Interventions
Salmonella typhi polysaccharide vaccine
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 20, 2026, 1:01 AM EDT